Hemostasis Today
NewsFeed
Headlines Hematology Health Medicine VTE ASH Plasma Donation
March, 2026
March 2026
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
3031  
Ney Carter Borges on Colchicine As 2ry Prevention in Atherosclerotic CVD
Ney Carter Borges/LinkedIn
Jan 28, 2026, 13:55

Ney Carter Borges on Colchicine As 2ry Prevention in Atherosclerotic CVD

Ney Carter Borges, Member Cardiologist of Global Physician Association at Cleveland Clinic Florida, shared on LinkedIn:

”Low-dose colchicine (0.5 mg/day) has emerged as an effective anti-inflammatory strategy for secondary prevention in atherosclerotic cardiovascular disease.

By inhibiting microtubule assembly, colchicine suppresses activation of the NLRP3 inflammasome, leading to reduced interleukin-1β and interleukin-6 signaling, key drivers of plaque inflammation and instability.

Clinical trial data demonstrate that colchicine significantly stabilizes atherosclerotic plaques, attenuates neutrophil activation, and reduces thrombogenic potential.

A pooled analysis of randomized trials shows a 25% relative reduction in major adverse cardiovascular events (HR ~0.75), with consistent reductions in myocardial infarction (≈23%), ischemic stroke (≈22%), and cardiovascular mortality (≈34%).

These benefits occur without an increase in non-cardiovascular mortality and with good tolerability in most patients.

Taken together, these findings position colchicine as a third pillar of secondary prevention, complementing lipid-lowering and antithrombotic therapies by targeting residual inflammatory risk in patients with established atherosclerosis.”

Ney Carter Borges on Colchicine As 2ry Prevention in Atherosclerotic CVD

Stay updated with Hemostasis Today.

Atherosclerosis colchicine Health Hematology Hemostasis Hemostasis News Hemostasis Today IL interleukin Medicine Ney Carter Borges NLRP3 thrombosis
NewsFeed